Status:
COMPLETED
Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma
Lead Sponsor:
Takeda
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
Brief Summary
This study is a survey in Japan of Cabozantinib tablets used to treat people with a type of kidney cancer called renal cell carcinoma. The study sponsor will not be involved in how the participants ar...
Detailed Description
The drug being tested in this study is called cabozantinib tablets. This tablet is being tested to treat people who have radically unresectable or metastatic renal cell carcinoma. This study is an ob...
Eligibility Criteria
Inclusion
- Patients with radically unresectable or metastatic renal cell carcinoma who do not meet the following exclusion criterion are eligible.
Exclusion
- A patient who has a history of hypersensitivity to any component of cabozantinib.
Key Trial Info
Start Date :
March 29 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 25 2024
Estimated Enrollment :
388 Patients enrolled
Trial Details
Trial ID
NCT04804813
Start Date
March 29 2021
End Date
July 25 2024
Last Update
April 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Takeda Selected Site
Tokyo, Japan